TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8807592

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 5 mg/day s.c during treatment period (Tx) for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Post-treatment period (PostGH) after discontinuation of rhGH
Number of subjects: 10
Study: 1522292

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide and oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen placebo
Number of subjects: 20
Study: 6094868

Group type: EXPERIMENTAL
Intervention: SBT/CPZ at 20 mg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SBT/CPZ at 40 mg/kg
Number of subjects: 43
Study: 30325529

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol for four days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for four days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 48
Study: 29924745

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TEX, 100 mg·wk)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Placebo treatment (PEX)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 3
Study: 26432791

Group type: EXPERIMENTAL
Intervention: Pavlik harness treatment (group I: start within 10 days, group II: 11 days to 3 weeks, group III: after 4 weeks)
Number of subjects: 62
Study: 25175668

Group type: EXPERIMENTAL
Intervention: Furlong Active stem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Furlong HAC stem
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both stem types
Number of subjects: 50
Study: 22475493

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 385

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 385
Study: 20643822

Group type: EXPERIMENTAL
Intervention: Muscle sparing thoracotomy (MST)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterolateral thoracotomy (PLT)
Number of subjects: 100
Study: 17269287

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16235185

Group type: EXPERIMENTAL
Intervention: Amplification of pfmdr1 in patient samples from 1995
Number of subjects: 0

Group type: COMPARATOR
Intervention: Samples collected in 2002
Number of subjects: 0
Study: 12120848

Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 505
Study: 10378663

Group type: EXPERIMENTAL
Intervention: High-flux dialysis membranes
Number of subjects: 660

Group type: COMPARATOR
Intervention: Low-flux dialysis membranes
Number of subjects: 660
Study: 7767393

Group type: EXPERIMENTAL
Intervention: Two doses of 250iu of anti-D Ig given at 28 and 34 weeks gestation
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1108
Study: 2310093

Group type: EXPERIMENTAL
Intervention: Amiloride inhalation (10(‐3) M)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amiloride inhalation (2 times a day for 3 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amiloride inhalation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 23
Study: 466843

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-treatment group (n = 10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acrophobic patients (n = 18)
Number of subjects: 18
Study: 31761434

Group type: EXPERIMENTAL
Intervention: Moment feedback
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Trunk inclination angle feedback
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lumbar flexion feedback
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 97
Study: 30327949

Group type: EXPERIMENTAL
Intervention: Mental nerve block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Infraorbital nerve block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study: 28416849

Group type: EXPERIMENTAL
Intervention: Mechanical cleaning of tongue coating
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no instruction for cleaning)
Number of subjects: 10
Study: 25994910

Group type: COMPARATOR
Intervention: Standard BFM therapy
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Extended, usually more intensive experimental treatment
Number of subjects: 291
Study: 24242264

Group type: EXPERIMENTAL
Intervention: SOLVE intervention
Number of subjects: 921

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 921
Study: 21957625

Group type: EXPERIMENTAL
Intervention: Tranexam
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 19048458

Group type: EXPERIMENTAL
Intervention: benzbromarone
Number of subjects: 69

Group type: COMPARATOR
Intervention: allopurinol
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 69

Group type: COMPARATOR
Intervention: uric acid
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GW9662 (PPARgamma antagonist) with benzbromarone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GW9662 (PPARgamma antagonist) with pioglitazone
Number of subjects: 69
Study: 16889452

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of Sertraline and HRT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11908535

Group type: EXPERIMENTAL
Intervention: Goal-training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 11715490

Group type: EXPERIMENTAL
Intervention: E1 group (esmolol 1 mg/kg)
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: E2 group (esmolol 2 mg/kg)
Number of subjects: 1830

Group type: COMPARATOR
Intervention: E0 group (0.9% NaCl)
Number of subjects: 1830
Study: 7499516

Group type: EXPERIMENTAL
Intervention: Transcutaneous extraction catheter (TEC) atherectomy device (2.7 mm, 4.0 mm, or 4.7 mm) followed by balloon dilatation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balloon dilatation alone
Number of subjects: 0
Study: 2309541

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg/kg rectally as premedication
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no midazolam)
Number of subjects: 20
Study: 445714

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 31961238

Group type: EXPERIMENTAL
Intervention: Packing with gelatin sponge
Number of subjects: 36

Group type: COMPARATOR
Intervention: Packing with nothing
Number of subjects: 36
Study: 29525478

Group type: EXPERIMENTAL
Intervention: 2015 guidelines with feedback/prompt device (2015F)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 2015 guidelines without feedback
Number of subjects: 124

Group type: COMPARATOR
Intervention: 2010 guidelines
Number of subjects: 124
Study: 26990304

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg IV)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 23
Study: 26246241

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU followed by 4,000 IU daily for 16 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (identical capsules for 16 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23394604

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20577225

Group type: EXPERIMENTAL
Intervention: α-lactalbumin (αlac)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sustained milk protein (SP)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Supra sustained milk protein (SSP)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All groups (αlac, SSP, SP)
Number of subjects: 87
Study: 18563688

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with pemetrexed and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy in pretreated patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted therapies
Number of subjects: 0
Study: 16630771

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg 3 times daily for 6 months)
Number of subjects: 52
Study: 12649866

Group type: EXPERIMENTAL
Intervention: Propofol infusion titrated to a Bispectral Index near 80
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propofol infusion titrated to a Bispectral Index near 60
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Electrical pulp stimulation (200 microamperes)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Electrical pain stimulation on the right upper thigh (80 mA)
Number of subjects: 8
Study: 10470750

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 64

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 64
Study: 7782484

Group type: EXPERIMENTAL
Intervention: Sertraline, 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sertraline, 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alprazolam, 1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2090472

Group type: EXPERIMENTAL
Intervention: Ticarcillin (3,080 mosmol.kg-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline (272 mosmol.kg-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tobramycin (248 mosmol.kg-1)
Number of subjects: 12
Study: 660035

Group type: EXPERIMENTAL
Intervention: Mild hypoxia (13.9% oxygen)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Severe hypoxia (11.1% oxygen)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal oxygen (20.9% oxygen)
Number of subjects: 8
Study: 31996244

Group type: EXPERIMENTAL
Intervention: Medical care based on the KTA framework
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 160
Study: 31465115

Group type: EXPERIMENTAL
Intervention: Suture-method catheter
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Standard perineural catheter
Number of subjects: 153

Group type: COMPARATOR
Intervention: Single-injection
Number of subjects: 153
Study: 28849797

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (self-etch)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (etch-and-rinse)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adper Single Bond 2 (control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clearfil SE Bond (control)
Number of subjects: 48
Study: 27324967

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 3450

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 3450
Study: 25099306

Group type: EXPERIMENTAL
Intervention: Communication skills training program (TG)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 115
Study: 22537421

Group type: EXPERIMENTAL
Intervention: Target hemoglobin level of 13.5 g/dL
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Target hemoglobin level of 11.3 g/dL
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin target with current smoking
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin target without current smoking
Number of subjects: 1432
Study: 19666395

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (2800 mg/daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-dose N-acetylcysteine (700 mg/daily)
Number of subjects: 21
Study: 17490437

Group type: EXPERIMENTAL
Intervention: Open irrigation tip (OIT) technology; temperature and power set at 50 degrees and 50 W, saline pump flow rate of 30 mL/min
Number of subjects: 53

Group type: COMPARATOR
Intervention: Radiofrequency (RF) energy delivery under ICE guidance
Number of subjects: 53
Study: 15237765

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12010358

Group type: EXPERIMENTAL
Intervention: Triple therapy with adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy with non-adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy with adherence and nadir below limit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy with adherence and nadir above limit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 0
Study: 9820445

Group type: EXPERIMENTAL
Intervention: 1.1% amino acid peritoneal dialysis solution (DAA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Glucose dialysate (DD)
Number of subjects: 105
Study: 7633704

Group type: EXPERIMENTAL
Intervention: Oxygen plus nasal pressure support ventilation (NPSV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxygen therapy alone
Number of subjects: 14
Study: 29214463

Group type: EXPERIMENTAL
Intervention: FOOT (60-min 9-a-side football match)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CON (rest)
Number of subjects: 15
Study: 27497779

Group type: EXPERIMENTAL
Intervention: NSAID (Ibuprofen 1800mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (CRP<1mg/l)
Number of subjects: 24
Study: 25600772

Group type: EXPERIMENTAL
Intervention: CHO/HAA (CHO + 13 g AA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHO/LAA (CHO + 6.5 g AA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CHO (1.2 g/kg body weight)
Number of subjects: 10
Study: 23745309

Group type: EXPERIMENTAL
Intervention: 0.5-hour infusion of 0.5 g every six hours for 24 hours
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2-hour infusion of 0.5 g every six hours for 24 hours
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2-hour infusion of 1 g every six hours for 24 hours
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 9
Study: 21420732

Group type: EXPERIMENTAL
Intervention: Azacitidine 50 mg/m² thrice weekly for 2 weeks every 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Weekly erythropoietin (in 7 patients)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 14
Study: 19335843

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative immunosuppressives (Mycophenolate mofetil, Leflunomide, Deoxyspergualin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologic agents (Tumor necrosis factor inhibitors, Alemtuzumab, Rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative networks in Europe and the USA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer agents
Number of subjects: 0
Study: 16412731

Group type: EXPERIMENTAL
Intervention: NuvaRing (contraceptive vaginal ring)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Combined Oral Contraceptive (COC)
Number of subjects: 8
Study: 15283740

Group type: EXPERIMENTAL
Intervention: Antidepressant Compliance Questionnaire (ADCQ)
Number of subjects: 357
Study: 11526357

Group type: EXPERIMENTAL
Intervention: Multilink stent
Number of subjects: 100

Group type: COMPARATOR
Intervention: GFX stent
Number of subjects: 100
Study: 9313060

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg twice a day for 3 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cotrimoxazol 8 mg and pipemidic acid 100 mg administered twice a day (control group)
Number of subjects: 50
Study: 8497669

Group type: EXPERIMENTAL
Intervention: Warm application with 3% saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cold application with 3% saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Warm application with 1/2 saline or normal saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cold application with 1/2 saline or normal saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All solutions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3% saline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Warm application
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cold application
Number of subjects: 18
Study: 3549162

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) and dilute betamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adenine arabinoside (ARA‐A) and dilute betamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adenine arabinoside (ARA‐A)
Number of subjects: 30
Study: 28719982

Group type: EXPERIMENTAL
Intervention: Deep friction massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisone injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Splinting and stretching
Number of subjects: 0
Study: 27792749

Group type: EXPERIMENTAL
Intervention: Non-randomised prospective studies (NPSs)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both NPSs and RCTs
Number of subjects: 547
Study: 24295873

Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir combination therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Tenofovir monotherapy
Number of subjects: 105
Study: 22654006

Group type: EXPERIMENTAL
Intervention: IBV Valves (treatment group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 73
Study: 20573750

Group type: EXPERIMENTAL
Intervention: FA + low‐ or moderate‐dose statin
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Low‐, moderate‐, or high‐dose statin monotherapy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: FA monotherapy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Statin monotherapy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: FA + statin
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: FA with or without statin
Number of subjects: 2000
Study: 18487900

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychosocial support therapy (Control)
Number of subjects: 0
Study: 15761748

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Physical intervention
Number of subjects: 130
Study: 12618567

Group type: EXPERIMENTAL
Intervention: PoleStriding with vitamin E
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PoleStriding with placebo
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vitamin E without exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo without exercise
Number of subjects: 52
Study: 10621925

Group type: EXPERIMENTAL
Intervention: Vinorelbine (30 mg/m2 on day 1 and day 8) and Cisplatin (100 mg/m2 on day 1) administered every three weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vinorelbine and Cisplatin
Number of subjects: 35
Study: 7669941

Group type: EXPERIMENTAL
Intervention: Carbocalcitonin (40 IU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (50 IU and 100 IU)
Number of subjects: 0
Study: 1940486

Group type: EXPERIMENTAL
Intervention: codeine
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: oxycodone
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: dextropropoxyphene
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: pentazocine
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: all opioids
Number of subjects: 944
Study: 6812820

Group type: EXPERIMENTAL
Intervention: Intensive education programme with regular home urine glucose testing
Number of subjects: 46

Group type: COMPARATOR
Intervention: Home blood glucose monitoring
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intensive education and cross-over studies
Number of subjects: 46
Study: 30073778

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pioglitazone (during extension phase 18-36 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 92
Study: 28913735

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% plus Clindamycin 1% gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adapalene 0.1% plus Clindamycin 1% gel
Number of subjects: 60
Study: 25645789

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 101
Study: 24451122

Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg with peginterferon alfa-2b/ribavirin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg with peginterferon alfa-2b/ribavirin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo with peginterferon alfa-2b/ribavirin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg for prior non-responders
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg for prior non-responders
Number of subjects: 27
Study: 22835054

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (TG)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Without thrombolytic therapy (WTG)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Thrombolytic therapy (TG) and Without thrombolytic therapy (WTG)
Number of subjects: 88
Study: 19378646

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy HIV/STD risk-reduction intervention (MDFT-HIV/STD)
Number of subjects: 0
Study: 17412790

Group type: EXPERIMENTAL
Intervention: Oral glucose supplementation (G)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No glucose supplementation (NG)
Number of subjects: 15
Study: 15054020

Group type: EXPERIMENTAL
Intervention: Housing First program (immediate housing without treatment prerequisites)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (housing contingent on treatment and sobriety)
Number of subjects: 225